Deutsche Bank Retains Buy Rating, $50 PT on Cardinal Health

Cardinal Health, Inc. CAH is poised for sustainable O/P, “given attractive NT leverage to the favorable generics landscape, while also possessing a myriad of LT growth drivers including specialty, ambulatory, nuclear and China,” Deutsche Bank reports. “We note a healthy balance sheet provides for NT upside optionality, with capital deployment likely focused on CAH's key growth initiatives (organic & inorganic) and maintaining a differentiated dividend policy (3rd highest yield amongst HC Service co's),” Deutsche Bank writes. “Based on attractive secular drivers & reasonable valuation, we retain a Buy rating and $50 PT.” Cardinal Health closed Monday at $44.46.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: ReiterationAnalyst RatingsCardinal HealthDeutsche BankHealth CareHealth Care Distributors
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!